• New logo and website created to reflect Leaf’s progression
• Better user experience with in-depth information on services and R&D
Norwich, UK - 24 January 2023 Leaf Expression Systems (Leaf), a plant-based contract research and product development company working to serve the global life sciences (human and animal health), agribiotech, food and consumer care industries has launched a new logo and website, leafexpressionsystems.com.
The logo and website reflect the progression Leaf has made from an academic spin-out to an established commercial organisation with a clear mission - to use…
The EU Commission launched the process regarding the adoption of an adequacy decision for EU-U.S. How the #adequacydecision for United States will improve #datatransfers between EU and U.S.?
An adequacy decision is a formal decision of the European Commission recognising that a country outside the EU provides an essentially equivalent level of data protection to that within the European Economic Area (EEA). There is no time limitation, however, the European Commission continuously monitors developments in countries and international organisations that could affect its decision. The adequacy…
Click here to view the January 2023 edition of The Meeting Place.
Monday 23rd January 2022: Creative Places is delighted to announce the appointment of Liam Nicholls to the position of CEO. Liam takes over from Jonathan Burroughs, who will remain fully involved in the business, focusing on client work.
Having joined Creative Places seven years ago, Liam’s expertise and tenacity has proven invaluable to the commercial property experts, which utilises its specialist, sector specific knowledge to help clients plan, create, manage and invest in collaborative places for people involved with research, R&D and innovation. Specifically…
o2h discovery, a preclinical Contract Research Organization which has an integrated drug discovery platform, is pleased to announce the second edition of the o2h kickstarter competition exclusively aimed towards supporting Australian early stage biotech companies. After the overwhelming response to the first competition, we are back with another edition to specifically support early stage Aus Biotech in their drug discovery programmes.
Aus Biotech has a globally competitive biotech ecosystem which has impact significantly higher than its size compared to the overall global Biotech sector. We…
New company created to enable commercial manufacture of new cell and gene therapies
Cellular Origins’ proprietary technology will address current barriers associated with cost-effective and efficient manufacture of cell and gene therapies at scale
Cambridge, UK, 17 January 2023: TTP plc (TTP), a leading independent technology and product development company, has today announced the launch of Cellular Origins, a TTP Company. Cellular Origins is a TTP spin-out, created to enable scalable, cost-effective and efficient manufacture of cell and gene therapies. Cellular Origins’ proprietary…
Expansion of five-year collaboration broadens established Organ-on-a-chip research demonstrating advanced performance of the PhysioMimix MPS
New research project to investigate the use of multi-organ MPS to improve estimation of human drug bioavailability in comparison to existing animal models
Cambridge, UK, 17th January 2023: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced that the U.S. Food and Drug Administration (FDA) and CN Bio have expanded their collaboration for the second time,…
Howard Group appoints Hilson Moran as Sustainability Consultant for its flagship development Unity Campus
Cambridge, 16th January 2023: As part of its aspiration to achieve a net zero carbon property portfolio by 2035, Howard Group, the Cambridge-based property investor and developer, is pleased to announce the appointment of Hilson Moran as Sustainability Consultant for the Group’s flagship development Unity Campus. Hilson Moran has been commissioned to develop a sustainability strategy and implementation plan for…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES TRANSFER OF AT307 TO HIKMA
License milestone to develop and commercialise ready-to-use medicine achieved
Arecor regains rights to AT282 following portfolio review at Hikma
Cambridge, UK, 12 January 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce a key advancement in the development of AT307, a ready-to-use (“RTU”) injectable medicine, with the transfer of development activities and achievement of the next license milestone…
Reddie & Grose, a UK and European firm of Patent, Trade Mark and Design attorneys, is delighted to announce that Dr Yumiko Kato has joined the firm as a Senior Associate. She will be working out of the London office.
Yumiko’s specialist field is chemistry where she holds particular experience in polymer chemistry, detergent compositions, printing ink compositions, material science, catalysis, nanotechnology and fluorocarbon chemistry. She also has extensive experience in pharmaceuticals and medical devices.
Having achieved a First Class Honours in MSci Chemistry from Imperial College…